REIT - Residential
Compare Stocks
5 / 10Stock Comparison
ELS vs NUVB vs SUI vs KYMR vs ARVN
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
REIT - Residential
Biotechnology
Biotechnology
ELS vs NUVB vs SUI vs KYMR vs ARVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | REIT - Residential | Biotechnology | REIT - Residential | Biotechnology | Biotechnology |
| Market Cap | $12.27B | $1.67B | $15.54B | $6.91B | $652M |
| Revenue (TTM) | $1.53B | $143M | $2.32B | $51M | $263M |
| Net Income (TTM) | $387M | $-146M | $1.55B | $-315M | $-81M |
| Gross Margin | 37.6% | 91.6% | 51.9% | 33.2% | 99.5% |
| Operating Margin | 33.8% | -105.0% | 24.0% | -7.0% | -44.0% |
| Forward P/E | 31.1x | — | 47.1x | — | — |
| Total Debt | $3.37B | $10M | $1.83B | $82M | $9M |
| Cash & Equiv. | $26M | $164M | $636M | $357M | $143M |
ELS vs NUVB vs SUI vs KYMR vs ARVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Aug 20 | May 26 | Return |
|---|---|---|---|
| Equity LifeStyle Pr… (ELS) | 100 | 95.5 | -4.5% |
| Nuvation Bio Inc. (NUVB) | 100 | 48.2 | -51.8% |
| Sun Communities, In… (SUI) | 100 | 84.6 | -15.4% |
| Kymera Therapeutics… (KYMR) | 100 | 265.3 | +165.3% |
| Arvinas, Inc. (ARVN) | 100 | 39.3 | -60.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ELS vs NUVB vs SUI vs KYMR vs ARVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ELS is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 12 yrs, beta 0.02, yield 3.2%
- Beta 0.02 vs NUVB's 2.04
NUVB ranks third and is worth considering specifically for growth exposure.
- Rev growth 7.0%, EPS growth 71.6%
- 7.0% revenue growth vs SUI's -27.9%
SUI carries the broadest edge in this set and is the clearest fit for valuation efficiency and defensive.
- PEG 0.91 vs ELS's 3.01
- Beta 0.26, yield 6.6%, current ratio 0.38x
- Better valuation composite
- 66.9% margin vs KYMR's -6.1%
KYMR is the clearest fit if your priority is long-term compounding.
- 154.4% 10Y total return vs SUI's 123.4%
- +190.7% vs ELS's +1.6%
ARVN is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.15, Low D/E 2.0%, current ratio 4.92x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.0% revenue growth vs SUI's -27.9% | |
| Value | Better valuation composite | |
| Quality / Margins | 66.9% margin vs KYMR's -6.1% | |
| Stability / Safety | Beta 0.02 vs NUVB's 2.04 | |
| Dividends | 6.6% yield, 9-year raise streak, vs ELS's 3.2%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +190.7% vs ELS's +1.6% | |
| Efficiency (ROA) | 12.2% ROA vs NUVB's -23.8%, ROIC 3.2% vs -54.3% |
ELS vs NUVB vs SUI vs KYMR vs ARVN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ELS vs NUVB vs SUI vs KYMR vs ARVN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ELS leads in 2 of 6 categories
SUI leads 1 • KYMR leads 1 • NUVB leads 0 • ARVN leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — NUVB and SUI each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SUI is the larger business by revenue, generating $2.3B annually — 45.2x KYMR's $51M. SUI is the more profitable business, keeping 66.9% of every revenue dollar as net income compared to KYMR's -6.1%. On growth, NUVB holds the edge at +26.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.5B | $143M | $2.3B | $51M | $263M |
| EBITDAEarnings before interest/tax | $727M | -$145M | $1.1B | -$352M | -$111M |
| Net IncomeAfter-tax profit | $387M | -$146M | $1.6B | -$315M | -$81M |
| Free Cash FlowCash after capex | $334M | -$126M | $884M | -$244M | -$276M |
| Gross MarginGross profit ÷ Revenue | +37.6% | +91.6% | +51.9% | +33.2% | +99.5% |
| Operating MarginEBIT ÷ Revenue | +33.8% | -105.0% | +24.0% | -7.0% | -44.0% |
| Net MarginNet income ÷ Revenue | +25.2% | -102.1% | +66.9% | -6.1% | -30.8% |
| FCF MarginFCF ÷ Revenue | +21.8% | -88.1% | +38.0% | -4.7% | -105.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.4% | +26.0% | +8.4% | +55.5% | -84.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -8.3% | +106.3% | +79.4% | +13.4% | -65.1% |
Valuation Metrics
SUI leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 11.6x trailing earnings, SUI trades at a 65% valuation discount to ELS's 32.8x P/E. Adjusting for growth (PEG ratio), SUI offers better value at 0.22x vs ELS's 3.17x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $12.3B | $1.7B | $15.5B | $6.9B | $652M |
| Enterprise ValueMkt cap + debt − cash | $15.6B | $1.5B | $16.7B | $6.6B | $517M |
| Trailing P/EPrice ÷ TTM EPS | 32.79x | -8.03x | 11.63x | -22.93x | -7.96x |
| Forward P/EPrice ÷ next-FY EPS est. | 31.11x | — | 47.12x | — | — |
| PEG RatioP/E ÷ EPS growth rate | 3.17x | — | 0.22x | — | — |
| EV / EBITDAEnterprise value multiple | 21.48x | — | 16.90x | — | — |
| Price / SalesMarket cap ÷ Revenue | 8.01x | 26.61x | 6.74x | 176.26x | 2.48x |
| Price / BookPrice ÷ Book value/share | 6.98x | 5.38x | 2.19x | 4.52x | 1.52x |
| Price / FCFMarket cap ÷ FCF | 36.74x | — | 17.98x | — | — |
Profitability & Efficiency
ELS leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
SUI delivers a 21.6% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-44 for NUVB. ARVN carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ELS's 1.85x. On the Piotroski fundamental quality scale (0–9), ELS scores 6/9 vs ARVN's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +21.3% | -44.1% | +21.6% | -25.0% | -14.3% |
| ROA (TTM)Return on assets | +6.8% | -23.8% | +12.2% | -22.3% | -9.3% |
| ROICReturn on invested capital | +7.6% | -54.3% | +3.2% | -24.9% | -22.4% |
| ROCEReturn on capital employed | +9.7% | -42.8% | +4.0% | -27.2% | -16.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 6 | 4 | 4 |
| Debt / EquityFinancial leverage | 1.85x | 0.03x | 0.25x | 0.05x | 0.02x |
| Net DebtTotal debt minus cash | $3.3B | -$154M | $1.2B | -$275M | -$134M |
| Cash & Equiv.Liquid assets | $26M | $164M | $636M | $357M | $143M |
| Total DebtShort + long-term debt | $3.4B | $10M | $1.8B | $82M | $9M |
| Interest CoverageEBIT ÷ Interest expense | 2.98x | -162.11x | 0.78x | -2119.53x | — |
Total Returns (Dividends Reinvested)
KYMR leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KYMR five years ago would be worth $19,212 today (with dividends reinvested), compared to $1,601 for ARVN. Over the past 12 months, KYMR leads with a +190.7% total return vs ELS's +1.6%. The 3-year compound annual growth rate (CAGR) favors KYMR at 45.0% vs ARVN's -25.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +6.8% | -43.8% | +4.1% | +16.3% | -11.2% |
| 1-Year ReturnPast 12 months | +1.6% | +136.3% | +7.8% | +190.7% | +52.8% |
| 3-Year ReturnCumulative with dividends | +0.2% | +197.5% | +4.5% | +205.1% | -58.7% |
| 5-Year ReturnCumulative with dividends | +3.5% | -58.3% | -10.2% | +92.1% | -84.0% |
| 10-Year ReturnCumulative with dividends | +106.7% | -51.8% | +123.4% | +154.4% | -36.5% |
| CAGR (3Y)Annualised 3-year return | +0.1% | +43.8% | +1.5% | +45.0% | -25.5% |
Risk & Volatility
ELS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ELS is the less volatile stock with a 0.02 beta — it tends to amplify market swings less than NUVB's 2.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ELS currently trades 91.7% from its 52-week high vs NUVB's 49.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.02x | 2.04x | 0.26x | 1.15x | 1.15x |
| 52-Week HighHighest price in past year | $69.00 | $9.75 | $137.85 | $103.00 | $14.51 |
| 52-Week LowLowest price in past year | $58.15 | $1.57 | $115.53 | $28.06 | $5.90 |
| % of 52W HighCurrent price vs 52-week peak | +91.7% | +49.4% | +91.5% | +82.2% | +70.2% |
| RSI (14)Momentum oscillator 0–100 | 47.5 | 59.1 | 42.2 | 54.1 | 42.6 |
| Avg Volume (50D)Average daily shares traded | 1.7M | 4.3M | 792K | 602K | 808K |
Analyst Outlook
Evenly matched — ELS and SUI each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ELS as "Buy", NUVB as "Buy", SUI as "Buy", KYMR as "Buy", ARVN as "Buy". Consensus price targets imply 157.3% upside for NUVB (target: $12) vs 11.3% for SUI (target: $140). For income investors, SUI offers the higher dividend yield at 6.63% vs ELS's 3.20%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $70.57 | $12.40 | $140.29 | $117.06 | $13.00 |
| # AnalystsCovering analysts | 21 | 9 | 20 | 26 | 26 |
| Dividend YieldAnnual dividend ÷ price | +3.2% | — | +6.6% | — | — |
| Dividend StreakConsecutive years of raises | 12 | — | 9 | — | — |
| Dividend / ShareAnnual DPS | $2.02 | — | $8.36 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +3.5% | 0.0% | +14.1% |
ELS leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). SUI leads in 1 (Valuation Metrics). 2 tied.
ELS vs NUVB vs SUI vs KYMR vs ARVN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ELS or NUVB or SUI or KYMR or ARVN a better buy right now?
For growth investors, Nuvation Bio Inc.
(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus -27. 9% for Sun Communities, Inc. (SUI). Sun Communities, Inc. (SUI) offers the better valuation at 11. 6x trailing P/E (47. 1x forward), making it the more compelling value choice. Analysts rate Equity LifeStyle Properties, Inc. (ELS) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ELS or NUVB or SUI or KYMR or ARVN?
On trailing P/E, Sun Communities, Inc.
(SUI) is the cheapest at 11. 6x versus Equity LifeStyle Properties, Inc. at 32. 8x. On forward P/E, Equity LifeStyle Properties, Inc. is actually cheaper at 31. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Sun Communities, Inc. wins at 0. 91x versus Equity LifeStyle Properties, Inc. 's 3. 01x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ELS or NUVB or SUI or KYMR or ARVN?
Over the past 5 years, Kymera Therapeutics, Inc.
(KYMR) delivered a total return of +92. 1%, compared to -84. 0% for Arvinas, Inc. (ARVN). Over 10 years, the gap is even starker: KYMR returned +154. 4% versus NUVB's -51. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ELS or NUVB or SUI or KYMR or ARVN?
By beta (market sensitivity over 5 years), Equity LifeStyle Properties, Inc.
(ELS) is the lower-risk stock at 0. 02β versus Nuvation Bio Inc. 's 2. 04β — meaning NUVB is approximately 9648% more volatile than ELS relative to the S&P 500. On balance sheet safety, Arvinas, Inc. (ARVN) carries a lower debt/equity ratio of 2% versus 185% for Equity LifeStyle Properties, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ELS or NUVB or SUI or KYMR or ARVN?
By revenue growth (latest reported year), Nuvation Bio Inc.
(NUVB) is pulling ahead at 699. 0% versus -27. 9% for Sun Communities, Inc. (SUI). On earnings-per-share growth, the picture is similar: Sun Communities, Inc. grew EPS 1427% year-over-year, compared to -23. 8% for Kymera Therapeutics, Inc.. Over a 3-year CAGR, ARVN leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ELS or NUVB or SUI or KYMR or ARVN?
Sun Communities, Inc.
(SUI) is the more profitable company, earning 59. 6% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 59. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELS leads at 33. 8% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ELS or NUVB or SUI or KYMR or ARVN more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Sun Communities, Inc. (SUI) is the more undervalued stock at a PEG of 0. 91x versus Equity LifeStyle Properties, Inc. 's 3. 01x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Equity LifeStyle Properties, Inc. (ELS) trades at 31. 1x forward P/E versus 47. 1x for Sun Communities, Inc. — 16. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUVB: 157. 3% to $12. 40.
08Which pays a better dividend — ELS or NUVB or SUI or KYMR or ARVN?
In this comparison, SUI (6.
6% yield), ELS (3. 2% yield) pay a dividend. NUVB, KYMR, ARVN do not pay a meaningful dividend and should not be held primarily for income.
09Is ELS or NUVB or SUI or KYMR or ARVN better for a retirement portfolio?
For long-horizon retirement investors, Equity LifeStyle Properties, Inc.
(ELS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 02), 3. 2% yield, +106. 7% 10Y return). Nuvation Bio Inc. (NUVB) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ELS: +106. 7%, NUVB: -51. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ELS and NUVB and SUI and KYMR and ARVN?
These companies operate in different sectors (ELS (Real Estate) and NUVB (Healthcare) and SUI (Real Estate) and KYMR (Healthcare) and ARVN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ELS is a mid-cap income-oriented stock; NUVB is a small-cap high-growth stock; SUI is a mid-cap deep-value stock; KYMR is a small-cap quality compounder stock; ARVN is a small-cap quality compounder stock. ELS, SUI pay a dividend while NUVB, KYMR, ARVN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.